{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-079600","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.619981+00:00","generated_at":"2026-06-04T06:08:19.979484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galera reports FY2023 net loss $59.1M; avasopasem NDA rejected; strategic review may lead to dissolution","bullets":["FY2023 net loss $59.1M ($1.33/sh); Q4 net loss $5.6M ($0.10/sh); cash $18.3M as of Dec 31, 2023.","Cash and equivalents $18.3M at year-end; expected to fund operations into Q2 2025.","FDA issued CRL for avasopasem NDA in Aug 2023; requires additional Phase 3 trial for resubmission.","Halted GRECO-2 (pancreatic) and GRECO-1 (NSCLC) trials after futility; workforce reduced 70% in Aug 2023.","Engaged Stifel to review strategic alternatives; CEO notes process could lead to dissolution."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-079600","json":"https://secwatch.observer/filing/0001193125-24-079600.json","markdown":"https://secwatch.observer/filing/0001193125-24-079600.md","text":"https://secwatch.observer/filing/0001193125-24-079600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/0001193125-24-079600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/d816795d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:08:19.979484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"970badd9644613d36123c6066eb04864a3b439d0","claim":"Galera Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/0001193125-24-079600-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}